agents are highly reactive chemicals that introduce alkyl groups into biologically active molecules and prevent normal functioning.
In a study of 93 chronic lymphocytic leukemia patients aged 32-68 years who had been treated previously with alkylating
agents and had failed treatment with fludarabine (70% had advanced disease), 31 (33%) of the patients had a complete or partial remission lasting a median of 7 months with use of Campath; 7 additional patients had a complete or partial remission that lasted for more than 1 year.
agents work by inducing changes in DNA molecules that lead to the death of the cancer cell.
The company stated TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating
and antimetabolite chemotherapeutics.
The center of the book focuses on interventions in oncology and their relationship to DNA maintenance processes, including alkylating
chemotherapeutics, MGMT, assessment of mismatch repair efficacy to predict the genesis or progression of cancer, and targeted base excision and nucleotide excision repair.
Radiotherapy and chemotherapy with alkylating
The final section of the text is dedicated to molecular principles applied to specific toxicants and includes chapters on alkylating
agents and "mustards," oxidative stress in the erythrocyte, aromatic amines and related toxic compounds, polycyclic aromatic hydrocarbon carcinogens, and acetaminophen.
Other therapy combinations significantly associated with high relative risks were abdominal/pelvic radiation and an alkylating
The classes of chemical compounds that cause cancer--including alkylating
agents, DNA-damaging agents, and toxicants that affect the cell cycle--vary in the mechanisms by which they cause the disease.
A Food and Drug Administration expert panel voted 14-1 to back accelerated approval of the monoclonal antibody alemtuzumab for chronic lymphocytic leukemia patients who fail first-line therapy with alkylating
agents and second-line therapy with fludarabine.
Using these and other factors, the retrospective study of more than 9,000 patients provides strong statistical evidence that approximately half of the secondary bone cancers observed can be blamed on radiation therapy or on chemotherapeutic alkylating
agents such as the frequently prescribed cyclophosphamide.